Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany’s healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by …
Read more on News-Medical-Net

Read more...

OncoMed Pharmaceuticals and Bayer HealthCare Expand Cancer Stem Cell Collaboration with Clinical Manufacturing Agreement
REDWOOD CITY, Calif., April 21, 2011 /PRNewswire/ — OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics targeting cancer stem cells, today announced it has expanded its collaboration with Bayer HealthCare. Bayer’s U.S. affiliate will manufacture clinical supplies of a second Wnt inhibitor in the alliance. Bayer will manufacture the bulk drug substance at its Berkeley …
Read more on redOrbit

Read more...

Conversely, he adds, a high-risk result could alert the clinical oncologist that the patient may be likely to demonstrate early progression , and so look for an alternative management strategy. Related posts: … Read more...

For those patients in the high-risk group, the result can alert the clinical oncologist to be ready for early progression and look for alternative management strategy, Dr Rosell said. Commenting on the research, which she was not … Read more...

In the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial, 302 men undergoing active surveillance were randomly assigned to receive either dutasteride, which belongs to the class of drugs known as 5-alpha reductase inhibitors, or placebo for 3 … The Genitourinary Cancers Symposium was cosponsored by the American Society of Clinical Oncology , the American Society for Radiation Oncology , and the Society of Urologic Oncology . … Read more...

Results from the Phase II trial combining Nexavar with capecitabine were presented in 2009 by Jose Baselga, M.D., chairman and professor of medicine at Vall d’Hebron Institute of Oncology in Barcelona and the principle investigator of the … Among these clinical trials are two ongoing randomized Phase II studies, including a trial to evaluate Nexavar plus gemcitabine or capecitabine in the second-line setting following progression on bevacizumab, and a trial to evaluate … Read more...

Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to NCI for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone Read more...

About clinical oncology Read more...

American Journal of Clinical Oncology publishes CTI’s OPAXIO phase II results against esophageal cancer
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent …
Read more on News-Medical-Net

Read more...